Frequency: Weekly (Goes into printing every Tuesday; On stands …
Launched on 21 December 2000, Chronicle Pharmabiz is the No. 1 Pharma news weekly in the South Asian markets; with a target readership that includes 100% coverage of top and middle management pharma professionals across the region.
2024 a landmark year for Indian pharma with advancements in ...
5 days ago · The year 2024 proved to be a landmark year for India's pharmaceutical sector, marked by notable advancements in drug manufacturing, healthcare technology, and accessibility. From introduction of revised Schedule M to improve manufacturing standards to an acceleration in healthcare technologies ...
India's most comprehensive portal on pharmaceutical News, …
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
Eton Pharma acquires Galzin, an US FDA approved treatment of …
1 day ago · Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it has acquired Galzin (zinc acetate). “This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra ...
News - Pharmabiz.com
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing
AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza ...
Dec 13, 2024 · AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced long-term results from the OlympiA phase 3 trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and ...
US FDA accepts and granted Priority Review status to …
Aug 16, 2024 · US FDA accepts and granted Priority Review status to AstraZeneca’s sBLA for Imfinzi to treat patients with limited-stage SCLC: Cambridge, UK Friday, August 16, 2024, 16:00 Hrs [IST]
Akeso begins patient enrollment in phase 3 trial of ivonescimab ...
Nov 4, 2024 · Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
May 3, 2024 · Boehringer Ingelheim’s Cyltezo to treat multiple chronic inflammatory diseases gets US FDA approval: Ridgefield, Connecticut Friday, May 3, 2024, 11:00 Hrs [IST]
US FDA grants accelerated approval to Novartis’ Scemblix for adult ...
Oct 31, 2024 · US FDA grants accelerated approval to Novartis’ Scemblix for adult patients with newly diagnosed Ph+ CML-CP: East Hanover Thursday, October 31, 2024, 12:00 Hrs [IST]